U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Abbott - 519686 - 04/28/2020
  1. Warning Letters

CLOSEOUT LETTER

Abbott MARCS-CMS 519686 —

Recipient:
Recipient Name
Randel Woodgrift
Recipient Title
Senior Vice President
Abbott

15900 Valley View Court
Sylmar, CA 91342
United States

mailto:Randel.woodgrift@abbott.com
Issuing Office:
Medical Device & Radiological Health Operations Division 3/West

United States

Dear Mr. Woodgrift:

The Food and Drug Administration has completed evaluation of your firm’s corrective actions in response to our Warning Letter (CMS #519686, April 12, 2017). Based on our evaluation, it appears that your firm has addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
Jessica Mu, Director of Compliance
Medical Device & Radiological Health Operations
Division 3/West

Back to Top